Literature DB >> 7664296

c-Myc and cyclin D3 (CcnD3) genes are independent targets for glucocorticoid inhibition of lymphoid cell proliferation.

K Rhee1, W Bresnahan, A Hirai, M Hirai, E A Thompson.   

Abstract

Glucocorticoids inhibit the expression of critical cell cycle-regulatory genes. The G1 cyclin gene CcnD3, which encodes cyclin D3, is inhibited by dexamethasone in P1798 murine T lymphoma cells. Glucocorticoids also inhibit expression of the catalytic partner of cyclin D3, Cdk4. Inhibition of these two genes results in a decrease in the ability to phosphorylate the Rb-1 tumor suppressor gene product. Stable transformation with SV40 T antigen expression vectors prevents glucocorticoid-mediated cell cycle arrest, which is consistent with the conclusion that glucocorticoids inhibit Rb-1 phosphorylation. Overexpression of cyclin D3 suffices to restore Rb-kinase activity in glucocorticoid-treated cells. Nevertheless, overexpression of cyclin D3 does not prevent glucocorticoid inhibition of cell proliferation. Cells transformed with Cdk4 expression vectors, with or without cyclin D3 expression vectors, also undergo G0 arrest in the presence of dexamethasone. Glucocorticoids inhibit c-Myc expression in lymphoid cells, and transient expression of c-Myc protein attenuates the lytic response in glucocorticoid-treated human leukemia cells (R. Thulasi, D. V. Harbour, and E. B. Thompson, J. Biol. Chem., 268: 18306-16312, 1993). However, P1798 cells stably transfected with c-Myc expression vectors are sensitive to glucocorticoid-mediated G0 arrest. Such transformants withdraw from the cell cycle when treated with dexamethasone. P1798 cells were transformed so as to express both c-Myc protein and cyclin D3 in the presence of glucocorticoids. These Myc/D3 cells continue to proliferate in the presence of dexamethasone, and virtually all of these cells are capable of entering S phase in the presence of the steroid. Rapid apoptotic cell death occurs when wild-type P1798 cells are treated with dexamethasone in serum-free medium. Myc-transformed and cyclin D3-transformed cells also die rapidly when treated with glucocorticoids in the absence of serum. T antigen transformants are resistant to glucocorticoid-mediated apoptosis in serum-free medium. Double transformants that express both cyclin D3 and c-Myc are also resistant to apoptosis in the presence of dexamethasone. We conclude that inhibition of both CcnD3 and c-Myc genes is critical to glucocorticoid-mediated G0 arrest. Furthermore, those genes that convey resistance to growth arrest also convey resistance to cell death.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7664296

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Regulation of macrophage migration inhibitory factor expression by glucocorticoids in vivo.

Authors:  Gunter Fingerle-Rowson; Peter Koch; Rachel Bikoff; Xinchun Lin; Christine N Metz; Firdaus S Dhabhar; Andreas Meinhardt; Richard Bucala
Journal:  Am J Pathol       Date:  2003-01       Impact factor: 4.307

2.  Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.

Authors:  Yana Pikman; Gabriela Alexe; Giovanni Roti; Amy Saur Conway; Andrew Furman; Emily S Lee; Andrew E Place; Sunkyu Kim; Chitra Saran; Rebecca Modiste; David M Weinstock; Marian Harris; Andrew L Kung; Lewis B Silverman; Kimberly Stegmaier
Journal:  Clin Cancer Res       Date:  2016-11-09       Impact factor: 12.531

3.  Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.

Authors:  Shuo-Chieh Wu; Loretta S Li; Nadja Kopp; Joan Montero; Bjoern Chapuy; Akinori Yoda; Amanda L Christie; Huiyun Liu; Alexandra Christodoulou; Diederik van Bodegom; Jordy van der Zwet; Jacob V Layer; Trevor Tivey; Andrew A Lane; Jeremy A Ryan; Samuel Y Ng; Daniel J DeAngelo; Richard M Stone; David Steensma; Martha Wadleigh; Marian Harris; Emeline Mandon; Nicolas Ebel; Rita Andraos; Vincent Romanet; Arno Dölemeyer; Dario Sterker; Michael Zender; Scott J Rodig; Masato Murakami; Francesco Hofmann; Frank Kuo; Michael J Eck; Lewis B Silverman; Stephen E Sallan; Anthony Letai; Fabienne Baffert; Eric Vangrevelinghe; Thomas Radimerski; Christoph Gaul; David M Weinstock
Journal:  Cancer Cell       Date:  2015-07-13       Impact factor: 31.743

Review 4.  Delivery of intracellular-acting biologics in pro-apoptotic therapies.

Authors:  Hongmei Li; Chris E Nelson; Brian C Evans; Craig L Duvall
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

5.  Among translational effectors, p70S6k is uniquely sensitive to inhibition by glucocorticoids.

Authors:  O J Shah; S R Kimball; L S Jefferson
Journal:  Biochem J       Date:  2000-04-15       Impact factor: 3.857

6.  Constitutive expression of ectopic c-Myc delays glucocorticoid-evoked apoptosis of human leukemic CEM-C7 cells.

Authors:  R D Medh; A Wang; F Zhou; E B Thompson
Journal:  Oncogene       Date:  2001-08-02       Impact factor: 9.867

7.  Glucocorticoid receptor-mediated cell cycle arrest is achieved through distinct cell-specific transcriptional regulatory mechanisms.

Authors:  I Rogatsky; J M Trowbridge; M J Garabedian
Journal:  Mol Cell Biol       Date:  1997-06       Impact factor: 4.272

8.  Involvement of c-myc in the resistance of non-obese diabetic mice to glucocorticoid-induced apoptosis.

Authors:  T C Martins; A P Aguas
Journal:  Immunology       Date:  1998-11       Impact factor: 7.397

9.  A functional and regulatory network associated with PIP expression in human breast cancer.

Authors:  Marie-Anne Debily; Sandrine El Marhomy; Virginie Boulanger; Eric Eveno; Régine Mariage-Samson; Alessandra Camarca; Charles Auffray; Dominique Piatier-Tonneau; Sandrine Imbeaud
Journal:  PLoS One       Date:  2009-03-05       Impact factor: 3.240

10.  GILZ mediates the antiproliferative activity of glucocorticoids by negative regulation of Ras signaling.

Authors:  Emira Ayroldi; Ornella Zollo; Alessandra Bastianelli; Cristina Marchetti; Massimiliano Agostini; Rosa Di Virgilio; Carlo Riccardi
Journal:  J Clin Invest       Date:  2007-05-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.